Table 1. Clinicopathological characteristics of eligible studies.
| Author | Year | Country | Ethnicity | Number | Histology | TNM stage | Sample | Assay | Follow-up (months) | Cut-off | Survival analysis | Hazard ratios | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OS | DFS/PFS/RFS | ||||||||||||
| Hao [14] | 2016 | China | Asian | 108 | 108 | Myeloma | I-III | Serum | qRT-PCR | 100 | Normal | OS/PFS | SC |
| Ali [15] | 2016 | America | Caucasian | 35 | Pancreatic Cancer | I-IIB | Frozen tissue | qRT-PCR | 70 | Normal | OS | SC | |
| Wang [4] | 2015 | China | Asian | 106 | 106 | Bladder Cancer | I-IV | Frozen tissue | qRT-PCR | 80 | Median | OS/RFS | HR/SC |
| Lim [16] | 2015 | British | Caucasian | 112 | 112 | Lymphoma | I-IV | Frozen tissue | qRT-PCR | 126 | Normal | OS/PFS | SC |
| Kalniete [17] | 2015 | Latvia | Caucasian | 50 | Breast cancer | I-IV | Frozen tissue | qRT-PCR | 84 | Median | OS | SC | |
| Chen [18] | 2014 | China | Asian | 99 | Colorectal Cancer | I-IV | Frozen tissue | Microarray | 84 | Normal | OS | HR/SC | |
| Wang [19] | 2014 | China | Asian | 108 | Gliomas | I-IV | Frozen tissue | qRT-PCR | 60 | Median | OS | HR/SC | |
| Wang (a) [20] | 2013 | China | Asian | 92 | 92 | Osteosarcoma | I- II | Frozen tissue | qRT-PCR | 133 | Median | OS/PFS | HR/SC |
| Wang (b) [21] | 2013 | China | Asian | 65 | HCC | I-III | Frozen tissue | qRT-PCR | 56 | Median | DFS | HR/SC | |
| Zhou [22] | 2013 | China | Asian | 104 | ESCC | NG | Frozen tissue | qRT-PCR | 36 | Mean | OS | SC | |
| Xia [23] | 2012 | Singapore | Asian | 50 | HCC | NG | Frozen tissue | qRT-PCR | 120 | Median | DFS | SC | |
| Marchini [24] | 2011 | Italy | Caucasian | 89 | 89 | Ovarian cancer | I-IV | Frozen tissue | qRT-PCR | 156 | Normal | OS/PFS | HR |
| Ueda [25] | 2010 | Japan | Asian | 353 | Gastric cancer | I-IV | Frozen tissue | qRT-PCR | 84 | Median | OS | HR/SC | |
TNM, tumor node metastasis; HCC, hepatocellular carcinoma; ESCC, esophageal squamous cell carcinoma; qRT-PCR, quantitative real-time PCR; OS, overall survival; PFS, progressive free survival; DFS, disease free survival; RFS, recurrence free survival; SC, survival curve.